JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

Home・Listă Acțiuni・Quanterix Corp

Quanterix Corp

Deschisă

SectorSănătate

3.38 8.68

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.33

Maxim

3.38

Indicatori cheie
By Trading Economics
Venit	10M -23M
Vânzări	3.7M 44M
Marjă de profit	-52.712
Angajați	450
EBITDA	15M -17M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	+63.2% upside

Dividende
By Dow Jones
Următoarele câștiguri	6 mai 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-145M 151M
Deschiderea anterioară	-5.3
Închiderea anterioară	3.38

Sentimentul știrilor

By Acuity

50%

176 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

5.34 / 6.015 Suport & Rezistență

Quanterix Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 mai 2026, 22:17 UTC

Câștiguri

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 mai 2026, 23:47 UTC

Câștiguri

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 mai 2026, 23:45 UTC

Câștiguri

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 mai 2026, 23:45 UTC

Câștiguri

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 mai 2026, 22:44 UTC

Achiziții, Fuziuni, Preluări

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 mai 2026, 22:43 UTC

Achiziții, Fuziuni, Preluări

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 mai 2026, 22:42 UTC

Achiziții, Fuziuni, Preluări

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 mai 2026, 22:42 UTC

Achiziții, Fuziuni, Preluări

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 mai 2026, 22:41 UTC

Achiziții, Fuziuni, Preluări

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 mai 2026, 22:41 UTC

Achiziții, Fuziuni, Preluări

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 mai 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Regis: Shareholders to Own About 51% of Combined Company

4 mai 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Regis: Board Unanimously Endorsed, Supported Deal

4 mai 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Regis: Deal Unanimously Recommended by Vault Board

4 mai 2026, 22:39 UTC

Achiziții, Fuziuni, Preluări

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 mai 2026, 22:38 UTC

Achiziții, Fuziuni, Preluări

Regis Resources to Acquire All Ordinary Shares in Vault

4 mai 2026, 22:38 UTC

Achiziții, Fuziuni, Preluări

Regis Resources, Vault Minerals Agree to Merger of Equals

4 mai 2026, 22:37 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 mai 2026, 22:26 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 mai 2026, 22:02 UTC

Câștiguri

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 mai 2026, 21:52 UTC

Câștiguri

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 mai 2026, 21:50 UTC

Câștiguri

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 mai 2026, 21:50 UTC

Câștiguri

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 mai 2026, 21:49 UTC

Câștiguri

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 mai 2026, 21:44 UTC

Câștiguri

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 mai 2026, 21:44 UTC

Câștiguri

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 mai 2026, 21:43 UTC

Câștiguri

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 mai 2026, 21:41 UTC

Câștiguri

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 mai 2026, 21:40 UTC

Câștiguri

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Comparație

Modificare preț

Quanterix Corp Așteptări

Obiectiv de preț

By TipRanks

63.2% sus

Prognoză pe 12 luni

Medie 5.5 USD 63.2%

Maxim 7 USD

Minim 4 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuanterix Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

2 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 2 analiști care au acordat evaluări ale acțiunilor Quanterix Corp - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

5.34 / 6.015Suport & Rezistență

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

There are no events.

Sentiment

By Acuity

176 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.